The FAA is adopting a new airworthiness directive (AD) for all Safran Helicopter Engines, S.A. (Safran) Model Arriel 2E engines. This AD was prompted by the determination that new or more restrictive airworthiness limitations are necessary. This AD requires revising the existing maintenance or inspection program to incorporate the airworthiness limitations section (ALS) of the existing approved aircraft maintenance program (AMP), as applicable. The FAA is issuing this AD to address the unsafe condition on these products.
Aug 5, 2026
· 1 min read
The FAA is superseding Airworthiness Directive (AD) 2024-02- 55, which applies to certain Bell Textron Canada Limited (BTCL) Model 505 helicopters. AD 2024-02-55 required initial and recurring inspections of the vertical stabilizer top end cap assembly and corrective action if a crack is found. Since the FAA issued AD 2024-02- 55, the manufacturer introduced a new one- piece vertical stabilizer machined top end cap assembly, which is implemented during production, and designed a new replacement for the vertical stabilizer machined top end cap assembly currently in service. This AD continues to require the inspection requirements of AD 2024-02- 55 and would limit the applicability to exclude certain serial numbered BTCL Model 505 helicopters with an improved design vertical stabilizer top end cap installed at production. This AD also requires replacing the vertical stabilizer top end cap assembly with an improved design top end cap assembly, which constitutes a terminating action for the recurring detailed visual inspections. The FAA is issuing this AD to address the unsafe condition on these products.
Aug 5, 2026
· 1 min read
The Environmental Protection Agency (EPA) approves revisions to the State of New Hampshire's Clean Air Act (CAA) title V operating permit program. These revisions amend the definitions of "hazardous air pollutant" and "regulated air pollutant" in New Hampshire regulations to remain consistent with Federal permitting and air toxics requirements in accordance with the CAA.
Aug 5, 2026
· 1 min read
The Environmental Protection Agency (EPA) is proposing to approve revisions to four State of California air districts' Clean Air Act title V program rules to remove emergency affirmative defense provisions. The four districts are the Amador County Air Pollution Control District (ACAPCD), the Calaveras County Air Pollution Control District (CCAPCD), the Great Basin Unified Air Pollution Control District (GBUAPCD), and the Northern Sierra Air Quality Management District (NSAQMD) ("Districts"). This proposed action is being taken in accordance with Federal regulations and the Clean Air Act (CAA or "Act"). We are taking comments on these proposed revisions and plan to follow with a final action.
Aug 5, 2026
· 1 min read
EPA is proposing significant new use rules (SNURs) under the Toxic Substances Control Act (TSCA) for certain chemical substances that were the subject of premanufacture notices (PMNs) and are also subject to an Order issued by EPA pursuant to TSCA. Once finalized, the SNURs would require persons who intend to manufacture (defined by statute to include import) or process any of these chemical substances for an activity that is proposed as a significant new use by this rulemaking to notify EPA at least 90 days before commencing that activity. The required notification initiates EPA's evaluation of the conditions of that use for that chemical substance. In addition, the manufacture or processing for the significant new use may not commence until EPA has conducted a review of the required notification, made an appropriate determination regarding that notification, and taken such actions as required by that determination.
Aug 5, 2026
· 1 min read
This action adds product(s) and service(s) to the Procurement List that will be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and deletes product(s) and service(s) from the Procurement List previously furnished by such agencies.
Aug 5, 2026
· 1 min read
The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for biosimilar user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development; review of certain applications for approval of biosimilar biological products; and each biosimilar biological product approved in a biosimilar biological product application. BsUFA III directs FDA to establish, before the beginning of each fiscal year, the amount of initial and annual biosimilar biological product development (BPD) fees, the reactivation fee, and the biosimilar biological product application and program fees for such year.
Aug 5, 2026
· 1 min read
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.
Aug 5, 2026
· 1 min read
The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2027 rates for GDUFA III fees.
Aug 5, 2026
· 1 min read
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes the FY 2027 rates for the small business establishment fee ($7,142), the non-small business establishment fee ($22,074), and the reinspection fee ($21,427) for outsourcing facilities; provides information on how the fees for FY 2027 were determined; and describes the payment procedures outsourcing facilities should follow.
Aug 5, 2026
· 1 min read
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Drug User Fee Amendments of 2023 (ADUFA V), authorizes FDA to collect user fees for certain animal drug applications and supplemental animal drug applications, for certain animal drug products, for certain establishments where such products are made, and for certain sponsors of such animal drug applications and/or investigational animal drug submissions. This notice establishes the fee rates for FY 2027.
Aug 5, 2026
· 1 min read
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
Aug 5, 2026
· 1 min read
The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2027, which apply from October 1, 2026, through September 30, 2027, and provides information on how the fees for FY 2027 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
Aug 5, 2026
· 1 min read
The Department is proposing revisions to regulations under the Black Lung Benefits Act (BLBA or the Act) governing authorization of self-insurers. These rules will determine the process for coal mine operators to apply for authorization to self-insure, the requirements operators must meet to qualify to self-insure, the amount of security self-insured operators must provide, and the types of security accepted for operators to self-insure.
Aug 5, 2026
· 1 min read
The Coast Guard is establishing a temporary safety zone for navigable waters on Lake Ontario, Olcott, NY. The safety zone is needed to protect personnel, vessels, and the marine environment from potential hazards associated with an over water fireworks display. Entry of vessels or persons into this zone is prohibited unless specifically authorized by the Captain of the Port, Sector Eastern Great Lakes, or their designated representative.
Aug 5, 2026
· 1 min read
